Skip to content

US · VTGN · BIOTECHNOLOGY

VistaGen Therapeutics, Inc. (VTGN) intrinsic value and stock valuation

$0.16as of 2026-11-21 · Mkt cap 12.19M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

VistaGen Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values VTGN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from VTGN’s statements →

VistaGen Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 vistagen.com

How the business is doing

Fiscal 2012–2026, USD

Revenue
$1.27M+3.1% 5y CAGRd
20122026
Net income
-$-69.69M
20122026
Free cash flow
-$-66.44M
20122026
Total equity
$35.5M-17.3% 5y CAGRd
20122026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2026, USD
20262025202420232022
Revenue$1.27M$490K$1.06M-$-230K$1.11M
Operating income-$-72.13M-$-55.97M-$-33.02M-$-59.27M-$-47.78M
Net income-$-69.69M-$-51.42M-$-29.36M-$-59.25M-$-47.76M
EPSd-$-1.83M-$-1.67M-$-1.52M-$-8.51M-$-7.24M
Operating cash flow-$-66.44M-$-42.1M-$-25.81M-$-49.72M-$-45.26M
Capital expenditure-$-150K-$-190K-$-60K-$-210K-$-200K
Free cash flow-$-66.44M-$-42.29M-$-25.87M-$-49.93M-$-45.46M
Total assets$48.6M$84.3M$123.7M$21.1M$74.6M
Total debt$1.04M$1.51M$2.12M$2.71M$3.04M
Net debt-$-29.75M-$-65.62M-$-117.05M-$-13.93M-$-65.1M
Total equity$35.5M$70.4M$114.3M$12.1M$64.7M
Cash and short-term investments$45.4M$80.5M$119.2M$16.6M$68.1M
Income statement
20262025202420232022
Revenue$1.27M$490K$1.06M-$-230K$1.11M
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$1.27M$490K$1.06M-$-230K$1.11M
Research and development expenses$55M$39.4M$20M$44.4M$35.4M
Selling, general and administrative expenses$18.4M$17.1M$14.1M$14.7M$13.3M
Other expenses$0.00$0.00$0.00$0.00$230K
Operating expenses$73.4M$56.5M$34.1M$59M$48.9M
Cost and expenses$73.4M$56.5M$34.1M$59M$48.9M
Interest income$2.44M$4.56M$3.35M$50K$20K
Interest expense$0.00$0.00$0.00$20K$0.00
Depreciation and amortization$730K$640K$570K$530K$710K
Ebitda-$-71.39M-$-50.78M-$-28.79M-$-58.74M-$-47.05M
Operating income-$-72.13M-$-55.97M-$-33.02M-$-59.27M-$-47.78M
Total other income/expenses, net$2.45M$4.56M$3.66M$30K$20K
Income before tax-$-69.68M-$-51.41M-$-29.36M-$-59.24M-$-47.76M
Income tax expense$10K$10K$0.00$10K$0.00
Net income-$-69.69M-$-51.42M-$-29.36M-$-59.25M-$-47.76M
Weighted average shares outstanding$38.1M$30.7M$19.4M$6.96M$6.6M
Weighted average diluted shares outstanding$38.1M$30.7M$19.4M$6.96M$6.6M
Balance sheet
20262025202420232022
Cash and short-term investments$45.4M$80.5M$119.2M$16.6M$68.1M
Net receivables$0.00$0.00$0.00$800K$2.75M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$46.9M$82.1M$120.7M$17.5M$71M
Property, plant and equipment, net$1.23M$1.81M$2.25M$2.77M$3.08M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.62M$2.27M$2.98M$3.58M$3.65M
Total assets$48.6M$84.3M$123.7M$21.1M$74.6M
Accounts payable$1.53M$650K$1.55M$2.47M$2.76M
Short-term debt$800K$560K$550K$590K$430K
Deferred revenue$1.71M$2.59M$790K$710K$1.24M
Total current liabilities$12.8M$12.6M$5.12M$4.57M$5.77M
Long-term debt$250K$950K$1.57M$2.12M$2.61M
Deferred revenue, non-current$0.00$390K$0.00$2.31M$1.56M
Total non-current liabilities$250K$1.34M$4.24M$4.43M$4.16M
Capital lease obligations$950K$1.51M$2.12M$2.61M$3.04M
Total liabilities$13M$14M$9.37M$9.01M$9.93M
Common stock$40K$30K$30K$10K$10K
Retained earnings-$-477.32M-$-407.63M-$-356.21M-$-326.85M-$-267.6M
Accumulated other comprehensive income (loss)-$0.00$10K$0.00$0.00$0.00
Total equity$35.5M$70.4M$114.3M$12.1M$64.7M
Total investments$14.6M$13.4M$0.00$0.00$0.00
Total debt$1.04M$1.51M$2.12M$2.71M$3.04M
Net debt-$-29.75M-$-65.62M-$-117.05M-$-13.93M-$-65.1M
Cash flow statement
20262025202420232022
Net income-$-69.69M-$-51.42M-$-29.36M-$-59.25M-$-47.76M
Depreciation and amortization$730K$640K$570K$530K$710K
Stock-based compensation$4M$4.32M$2.18M$3.34M$3.48M
Change in working capital-$-940K$4.76M$790K$2.03M-$-1.92M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$830K$5.68M$520K-$-930K$1.69B
Net cash provided by operating activities-$-66.44M-$-42.1M-$-25.81M-$-49.72M-$-45.26M
Investments in property, plant and equipment-$-150K-$-190K-$-60K-$-210K-$-200K
Acquisitions, net$0.00$0.00$0.00-$-530K$0.00
Net cash used for investing activities-$-880K-$-13.15M-$-60K-$-740K-$-200K
Common stock issued$30.9M$3.01M$129.4M$100K$4.44M
Common stock repurchased$0.00$0.00$0.00-$-170K$0.00
Dividends paid$0.00$0.00$0.00$0.00-$-945.1M
Net cash used for financing activities$31M$3.21M$128.4M-$-1.04M$10.5M
Net change in cash-$-36.34M-$-52.03M$102.5M-$-51.5M-$-34.97M
Cash at end of period$30.8M$67.1M$119.2M$16.6M$68.1M
Operating cash flow-$-66.44M-$-42.1M-$-25.81M-$-49.72M-$-45.26M
Capital expenditure-$-150K-$-190K-$-60K-$-210K-$-200K
Free cash flow-$-66.44M-$-42.29M-$-25.87M-$-49.93M-$-45.46M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About VistaGen Therapeutics, Inc.

        VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.

        CEO
        Shawn K. Singh
        Employees
        41
        Beta
        0.40

        Explore

        Frequently asked questions

        What is the intrinsic value of VistaGen Therapeutics, Inc. (VTGN)?

        InvestorsCraft does not currently publish an intrinsic value for VTGN. How the IC value is calculated.

        Is VTGN undervalued?

        InvestorsCraft does not publish an undervaluation signal for VTGN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.